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Abstract
Introduction: Despite notable progress towards PMTCT, only 50% of HIV-exposed infants in sub-Saharan Africa were tested
within the first 2 months of life and only 30% of HIV-infected infants are on antiretroviral treatment. This study assessed HIV
prevalence in infants and children receiving care at various service entry points in primary healthcare facilities in Uganda.
Methods: A total of 3600 infants up to 24 months of age were systematically enrolled and tested at four regional hospitals
across Uganda. Six hundred infants were included and tested from six facility entry points: PMTCT, immunization, inpatient,
nutrition, outpatient and community outreach services.
Findings: The traditional EID entry point, PMTCT, had a prevalence of 3.8%, representing 19.6% of the total HIV-positive
infants identified in the study. Fifty percent of the 117 identified HIV-positive infants were found in the nutrition wards, which
had a prevalence of 9.8% (p < 0.001 compared to PMTCT). Inpatient wards had a prevalence of 3.5% and yielded 17.9% of
the HIV-positive infants identified. Infants tested at immunization wards and through outreach services identified 0.8% and
1.7% of the HIV-positive infants respectively, and had a prevalence of less than 0.3%.
Conclusions: Expanding routine early infant diagnosis screening beyond the traditional PMTCT setting to nutrition and
inpatient entry points will increase the identification of HIV-infected infants. Careful reflection for appropriate testing
strategies, such as maternal re-testing to identify new HIV infections and HIV-exposed infants in need of follow-up testing and
care, at immunization and outreach services should be considered given the expectedly low prevalence rates. These findings
may help HIV care programmes significantly expand testing to improve access to early infant diagnosis and paediatric treatment.
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1 | INTRODUCTION
Only 51% of HIV-positive children across 21 high-burden sub-
Saharan African countries are on lifesaving antiretroviral ther-
apy (ART) [1]. Data from this region show that in the absence of
treatment, peak mortality for infants infected with HIV in utero
or intrapartum occurs between 2 and 3 months of age [2], and
approximately 50% of untreated HIV-positive infants die by
2 years of age [3]. Early initiation on ART for HIV-positive
infants has been shown to significantly reduce mortality [4].
Under the Global Plan Towards the Elimination of New HIV
Infections Among Children by 2015 and Keeping Their
Mothers Alive, prevention of mother to child transmission
(PMTCT) coverage increased significantly between 2009 and
2015, from 37% to 90% [1]. Furthermore, 20 of the 21 Global
Plan priority high-burden countries currently offer lifelong
ART to pregnant women (WHO Option B+) rather than time-
limited prophylaxis (WHO Option A or Option B). As a result,
over 90% of pregnant women who access ART for PMTCT
have access to lifelong therapy [1]. Similarly, in Uganda where
the HIV prevalence rate among pregnant mothers is 7.6%,
approximately 85% of newly diagnosed pregnant mothers
were initiated on ART in 2016. Conversely, the increase in
ART coverage amongst children over the same time period,
from 10% in 2009 to 35% in 2015, was significantly lower
and overall ART coverage among infants is less than 50% of
maternal coverage. This is largely because HIV-exposed infants
either do not receive a timely, actionable result or are not
tested at all. In 2015, only 51% of HIV-exposed infants
received a virological test by 2 months of age, the WHO-rec-
ommended time period for a first early infant diagnosis (EID)
test [1]. Improvements in EID coverage have been minimal in
recent years and some countries have reported testing pla-
teaus or declines [1].
Doubling down on efforts to find HIV-exposed and HIV-pos-
itive children is necessary. Evidence demonstrates that in
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many contexts relying solely on PMTCT programmes to
achieve universal EID coverage is inadequate and paediatric
ART coverage stagnates without strengthened diagnostic pro-
grammes targeting children [5,6]. To make a significant shift
from the status quo, a comprehensive range of infant testing
strategies specific to both high and low prevalence settings –
and a clear articulation of how to implement them – are
needed.
To date, provider-initiated HIV testing and counseling
(PITC) has been recommended by WHO as a mechanism to
identify HIV-exposed infants who are lost to follow up from or
never enrolled in the PMTCT cascade. Indeed, many countries
have already incorporated paediatric PITC recommendations
into national guidelines [7,8]. However, persistently low EID
coverage – which translates into low paediatric ART coverage
– suggests that despite the inclusion of paediatric PITC in pol-
icy, uptake and practice are insufficient.
Several studies have examined the implementation of PITC
or routine testing at different healthcare facility entry points
in isolation, but to date no studies have compared HIV
prevalence at multiple entry points simultaneously. Many of
these studies also lack a comparator, such as the traditional
PMTCT entry point [9–13]. Furthermore, many do not
employ random, systematic, or consecutive sampling, but
rather targeted testing, which means that the underlying
prevalence for individual entry points is difficult to ascertain
[9,10]. Therefore, this study was conducted to determine and
compare paediatric HIV prevalence at several healthcare
facility entry points in order to better understand how to
identify more HIV-positive children in resource-limited
settings.
2 | METHODS
This was a cross-sectional prospective study of infants below
the age of 2 years presenting at the primary healthcare facil-
ity entry points at four hospitals in Uganda. The four health-
care facilities included in this study were: Mulago National
Referral Hospital; St. Mary’s Hospital, Lacor; Mbale Regional
Referral Hospital; and Mbarara Regional Referral Hospital.
Infants were recruited from six entry points at each health-
care facility: Immunization (Expanded Programme on Immu-
nization)/well-child clinic, paediatric outpatient, paediatric
inpatient, nutrition, outreach and PMTCT, which is the tradi-
tional setting for EID testing. A total of 3600 infants less than
2 years of age were included in the study. One hundred and
fifty infants were enrolled at each of the six entry points per
hospital. Data collection occurred between September 2014
and August 2015.
Patients were systematically sampled and enrolled at each
entry point. Due to low daily volumes (<16 infants/day), con-
secutive enrolment was employed at the nutrition and PMTCT
entry points. Systematic sampling across all attending patients
was used within the immunization, paediatric outpatient, pae-
diatric inpatient and outreach settings due to high patient vol-
ume, to ensure unbiased patient selection. It was predicted
that each entry point could enrol 15 infants per day per study
nurse; therefore, if an entry point typically had 16 to 30, 31
to 45, or 46 to 60 eligible infants per day each study nurse
would enrol every other, third, or fourth infant respectively.
Study systems were put in place to ensure no infant was
enrolled at multiple entry points. The study objectives and
study enrolment processes, including pre-HIV test counselling,
were explained to the mother or guardian of each infant
invited to participate in the study at non-PMTCT entry points
before they signed a letter of informed consent.
Demographic and clinical data were collected for each
infant and mother (if present) using standardized study-speci-
fic forms and study-specific identification numbers. All enrolled
infants underwent both serological and virological testing to
determine HIV exposure and HIV infection status respectively.
Dried blood spot specimens (DBS) were collected for virologi-
cal testing and rapid serological diagnostic tests were con-
ducted on each patient. Both tests were conducted on each
enrolled infant regardless of the respective results, except for
infants at the PMTCT entry point who did not receive a sero-
logical screen as their exposure status was already known.
Healthcare facility staff, including nurses, clinical officers and
laboratory technicians, were trained on study procedures, how
to conduct DBS specimen collection and rapid diagnostic test-
ing, and demonstrated proficiency before study commence-
ment. Finally, maternal HIV status was determined if she
provided verbal identification or by confirmation from facility
records, if her infant included in the study was HIV-positive,
or if her infant was positive by RDT. All mothers were offered
HIV testing per the national guidelines.
Rapid diagnostic testing was performed using the Alere
DetermineTM HIV-1/2 (Waltham, MA, USA). One drop of whole
blood was collected using a lancet heel stick, applied to the
test strip, and tested per manufacturer’s instructions. Either
that same lancet heel stick or a fresh draw was used to collect
an additional 3 to 5 drops of whole blood that were applied
to a filter paper card (Whatman 903, GE Healthcare Bio-
sciences, Pittsburgh, PA). Specimens were dried overnight at
room temperature and shipped weekly for testing to the Cen-
tral Public Health Laboratories in Kampala, Uganda. Dried
blood spot specimens were processed and tested with the
Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM 96)
HIV-1 Qualitative Test (Roche Molecular Diagnostics, Branch-
burg, NJ, USA) according to the manufacturer’s instructions.
Any infants with positive rapid diagnostic test or virological
test result were referred to PMTCT for post-test counselling
and inclusion in care and treatment per the national standard
of care guidelines.
This study was approved by the Mildmay Uganda Research
Ethics Committee, Uganda National Council for Science and
Technology, Mulago Hospital Research and Ethics Committee,
Institutional Review Committee at St. Mary’s Hospital, Lacor,
and the Chesapeake Institutional Review Board in the USA.
Statistical analysis was performed with the R statistical soft-
ware (Version 3.3.2, Free Software Foundation, Boston, MA,
USA) and GraphPad Prism (Version 6.0, La Jolla, CA, USA).
Infants from like entry points were pooled across hospitals for
primary analyses. Two-sample and multi-sample comparisons
were done using the nonparametric rank-based Wilcoxon-
Mann–Whitney and Kruskal–Wallis tests respectively. Multi-
testing p-value adjustment for the p values from logistic
regression models was performed according to Hothorn et al.
[14] and controls family-wise error rate. Binomial probability
confidence interval was computed using the Wilson method
[15].
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3 | RESULTS
A total of 3600 infants were enrolled (47% female) (Table 1).
Just over half of the infants included were 8 months of age or
younger (56%) and 74% of infants were 12 months of age or
younger. The median age at study inclusion was 7 months
(IQR: 2 to 13 months). In the HIV-positive study population,
40% of infants were 8 months of age or younger, and 57%
were 12 months of age or younger. The median age at study
inclusion for HIV-positive infants was 11 months (IQR: 5 to
15 months). Most (80%) infants were breastfeeding at the
time of testing; however, only 46% of the HIV-positive infants
were breastfeeding at the time of testing (p < 0.001). Approx-
imately 50% of infants had attended a healthcare facility at
some point within the previous year in all study groups.
Of the 3600 infants enrolled in the study, two were
excluded from additional analyses. One infant from the immu-
nization entry point had an invalid (failed) virological test
result, and one infant from the PMTCT entry point did not
have a recorded virological test result. A total of 117 (3.3%,
95% CI: 2.7% to 3.9%) infants were identified as HIV-positive.
Infants tested at the traditional PMTCT entry point had a
prevalence of 3.8% (95% CI: 2.6% to 5.7%), yielding approxi-
mately 20% of all identified HIV-positive infants (Table 2, Fig-
ure 1a). Fifty percent of the 117 HIV-positive infants
identified in this study were found at the nutrition entry point,
which had a prevalence of 9.8% (95% CI: 7.7% to 12.5%)
(p < 0.001, compared to PMTCT). The inpatient entry point
had a similar yield of HIV-positive infants (18%) as the
PMTCT entry point and a prevalence of 3.5% (95% CI: 2.3 to
5.3). While the prevalence at the outpatient entry point was
relatively modest at 1.8% (95% CI: 1.0% to 3.3%), 11 HIV-
positive infants or 9.4% of all identified HIV-positive infants,
were identified. The immunization and community outreach
entry points had the lowest prevalence at less than 0.3% and
also the smallest number of HIV-positive infants were identi-
fied, one and two respectively.
The overall prevalence of HIV-positive infants was consis-
tent across facilities (3.1% to 4.2%) besides Lacor, which had a
lower prevalence (1.9%). The number and proportion of HIV-
positive infants was generally lower at Lacor across most
entry points, particularly the nutrition entry point (p < 0.001).
The odds ratios for identifying an HIV-positive infant at
each entry point were calculated as compared to the tradi-
tional PMTCT entry point while adjusting for facilities using a
logistic regression model (Figure 1b). Only the nutrition entry
point had an odds ratio greater than one (2.8; 95% CI: 1.7 to
4.5; p < 0.001), indicating that the infants attended nutrition
entry points were three times more likely to be HIV-positive
than those at PMTCT. The inpatient entry point had an odds
ratio of 0.9 (95% CI: 0.5 to 1.7; p = 0.756). The outpatient
entry point had an odds ratio of 0.5 (95% CI: 0.2 to 1.0;
p = 0.041). The outreach and immunization entry points had
odds ratios of 0.1 (95% CI: 0.0 to 0.4; p = 0.001) and 0.0
(95% CI: 0.0 to 0.3; p = 0.002) respectively, indicating signifi-
cantly lower likelihood of infants at outreach and immuniza-
tion being HIV-positive compared to PMTCT.
Mechanisms to leverage the Expanded Programme on
Immunization as a setting to provide access to EID are fre-
quently discussed in the global paediatric HIV community. We,
therefore, also determined the odds of identifying an HIV-pos-
itive infant at each entry point compared to the immunization
entry point (Figure 1c). The nutrition, PMTCT, and inpatient
entry points had odds ratios of 65.7 (95% CI: 9.1 to 474.7;
p < 0.001), 23.9 (95% CI: 3.2 to 177.3; p = 0.002), and 21.7
(95% CI: 2.9 to 161.7; p = 0.003) respectively, indicating that
each would be significantly more efficient to identify HIV-posi-
tive infants compared to the immunization entry point. The
odds of identifying HIV-positive infants at outpatient and out-
reach entry points were also higher than at immunization clin-
ics, 11.2 (95% CI: 1.4 to 86.7; p = 0.021) and 2.0 (95% CI:
0.2 to 22.1; p = 0.572) respectively.
The proportion of HIV-positive infants (and mothers) identi-
fied at non-PMTCT entry points who were previously enrolled
in PMTCT was determined in order to understand whether
HIV-positive infants identified in the study were missed in the
traditional EID setting. A mother was identified as HIV-posi-
tive if she provided verbal identification or by confirmation
from facility records, if her infant included in the study was
HIV-positive, or if her infant was positive by RDT. By these
three definitions, 324 mothers were HIV-positive for a total
of 325 HIV-exposed infants (one set of twins). Only 60% of all
Table 1. Demographic characteristics of study participants
Total,
N = 3,600
Total, N = 3,481
Total,
N = 117
All infants
HIV-negative
infants
HIV-positive
infants
Gender, n (%)
Female 1,691 (47) 1,638 (47) 52 (44)
Male 1,909 (53) 1,843 (53) 65 (55)
Age group, n (%)
0 to 4 months 1346 (37) 1317 (38) 28 (24)
4 to 8 months 666 (18) 647 (19) 19 (16)
8 to 12 months 643 (18) 622 (18) 21 (18)
12 to 16 months 448 (12) 424 (12) 23 (20)
16 to 20 months 291 (8) 279 (8) 12 (10)
20 to 24 months 206 (6) 192 (6) 14 (12)
Median age, months (IQR)
PMTCT 1 (1 to 2) 1 (1 to 2) 4 (2 to 10)
Nutrition 12 (8 to 17) 12 (8 to 17) 13 (7 to 17)
Inpatient 9 (5 to 14) 9 (5 to 14) 13 (5 to 15)
Outpatient 9 (5 to 15) 9 (5 to 15) 8 (6 to 14)
Immunization 4 (2 to 9) 4 (2 to 9) 1 (1 to 1)
Outreach 8 (4 to 13) 8 (4 to 13) 20 (19 to 22)
Total 7 (2 to 13) 7 (2 to 13) 11 (5 to 15)
Breastfeeding status, n (%)
Currently
breastfeeding
2841 (79) 2784 (80) 55 (47)
Not
breastfeeding
737 (20) 677 (19) 60 (51)
Unknown 22 (1) 20 (1) 2 (2)
Facility attendance within previous year, n (%)
Attended 1741 (48) 1676 (48) 64 (55)
Did not attend 1227 (34) 1197 (34) 30 (26)
N/A 632 (18) 608 (17) 23 (2)
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HIV-positive mothers were enrolled in PMTCT (Table 3).
Most (80%) HIV-positive mothers knew their HIV status, and
74.9% of those mothers were enrolled in PMTCT. Of those
HIV-positive mothers with an HIV-positive infant, only 18.1%
were enrolled in PMTCT. Forty-seven percent of HIV-positive
mothers with an HIV-positive infant knew their status, and of
those only 38.7% were enrolled in PMTCT.
4 | DISCUSSION
While previous studies provided clues to the highest impact
entry points for identifying HIV-positive infants [9–13], these
findings present the first evidence of differences in HIV preva-
lence amongst children accessing care at different health facil-
ity entry points in a low resource, generalized HIV epidemic.
These data demonstrate high HIV prevalence among infants
presenting for care at nutrition, inpatient, and PMTCT entry
points. In particular, prevalence at nutrition wards was over
two times higher than in the routine PMTCT setting. HIV
prevalence was much lower at the immunization and outreach
entry points; the likelihood of identifying a HIV-positive infant
was more than 20 times greater in nutrition and inpatient
wards than in immunization clinics. These results suggest a
comprehensive strategy for expanded routine EID screening
at entry points beyond PMTCT that can help maximize the
identification of HIV-positive infants in resource-limited
settings.
In generalized epidemic settings, the World Health Organi-
zation (WHO) strongly recommends that infants and children
with unknown HIV status who are admitted at inpatient or
nutrition entry points should be routinely tested for HIV. Fur-
thermore, WHO conditionally recommends offering testing in
outpatient or immunization entry points [16,17]. The findings
of this study align with these WHO recommendations. How-
ever, while these policies already exist in many high burden
countries [8], they are not widely put into practice and
PMTCT remains the primary testing point for early infant
diagnosis. Up to 23% of mother-infant pairs do not access
PMTCT in high HIV burden countries and significant propor-
tions are lost-to-follow-up during EID testing, pre-ART as well
as after ART initiation [18,19]. These infants may subsequently
present at nutrition and inpatient wards, as a result of the sig-
nificant morbidity amongst untreated HIV-positive infants
[2,3]. As countries seek to expand the coverage of paediatric
treatment, this study highlights the importance of implement-
ing more diverse testing strategies outside of PMTCT to
expand access to EID and reduce the current gaps in access
to paediatric HIV care.
Our results support universal testing of infants in nutrition
and inpatient entry points within generalized epidemic set-
tings. While widespread virological testing of all infants who
Table 2. Number and prevalence of HIV to positive infants by entry point and facility
PMTCT Immunization Inpatient Nutrition Outpatient Outreach Total
Number 23 1 21 59 11 2 117
Prevalence
(95% CI)
3.8%
(2.6 to 5.7)
0.2%
(0.0 to 0.9)
3.5%
(2.3 to 5.3)
9.8%
(7.7 to 12.5)
1.8%
(1.0 to 3.3)
0.3% (0.1 to 1.2) 3.3% (2.7 to 3.9)
Lacor 6.0% 0.0% 0.0% 4.0% 0.7% 0.7% 1.9% (1.2 to 3.0)
Mbale 1.3% 0.7% 0.7% 13.3% 2.0% 0.7% 3.1% (2.2 to 4.5)
Mbarara 4.7% 0.0% 6.7% 11.3% 2.7% 0.0% 4.2% (3.1 to 5.7)
Mulago 3.3% 0.0% 6.7% 10.7% 2.0% 0.0% 3.8% (2.7 to 5.2)
Figure 1. HIV prevalence proportions and odds ratios across facility
entry points. (a) HIV prevalence in each facility entry point. (b)
Odds ratios to identify an HIV-positive infant in each facility entry
point compared to the traditional PMTCT setting. (c) Odds ratios to
identify an HIV-positive infant in each facility entry point compared
to the immunization entry point.
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present for care at healthcare facilities may be difficult to
implement or unnecessary in every setting, universal testing
at nutrition and inpatient entry points in high prevalence
settings may play a key role in expanding paediatric ART
access. In this context, the use of point-of-care EID technolo-
gies in these settings, as logistics and budgets warrant, to
allow for immediate testing, same-day return of results, and
rapid clinical decision-making is a potential opportunity or tool
for health programmes to consider. Previous evidence
suggests that rapid EID testing leads to faster ART initiation
[20], while earlier ART initiation can reduce infant mortality
[4].
Universal testing in lower-yield settings, such as immuniza-
tion and community outreach entry points, may not be as effi-
cient in identifying HIV-positive infants, but alternative
strategies for identifying high-risk infants could be pursued.
Previous studies have investigated the acceptability and feasi-
bility of expanding EID testing services outside of PMTCT –
including community outreach, door-to-door testing, and
immunization settings [11]. Vaccination rates are high across
many countries, and immunization is an entry point where sig-
nificant numbers of infants present. While screening of all
infants at immunization has been shown to be feasible
[11,21], the results of this study suggest that universal EID
testing at immunization and outreach may be relatively ineffi-
cient due to the low prevalence of HIV-positive infants. Earlier
studies in Malawi and Nigeria presented similar low preva-
lence of HIV-positive infants at immunization [10,22]. Further-
more, the complexity and cost of integrating universal EID
into congested immunization clinics has been previously noted
[11,23] and may not be an effective use of limited resources.
Immunization and outreach entry points could, however, be
ideal settings for maternal re-testing and symptom-driven
screening to identify HIV-exposed infants for referral into pae-
diatric HIV care [24].
Of the HIV-positive infants in the study the median age
was almost 1 year, and over 50% had previously attended a
healthcare facility, suggesting that opportunities to identify
either the HIV-infected mothers or their infants earlier
were missed. Option B+, lifelong ART for HIV-positive preg-
nant women, was adopted in Uganda in 2012 and has since
achieved national coverage. In 2014, Uganda reported >95%
ART coverage for its PMTCT population, thus exceeding the
Global Plan target of 90%, and the mother-to-child
transmission rate was 4.2% [1]. In this study, we found that
75% of all HIV-positive mothers identified in non-PMTCT
entry points who knew their status had enrolled in PMTCT.
Understanding the reasons for the gap between status
knowledge and willingness, interest, or ability to enrol in
PMTCT will be critical to further reducing mother-to-child
transmission. This gap was particularly large in the study
population of HIV-positive mothers who had HIV-positive
infants; of the mothers in this population who knew
their HIV-positive status, less than 40% had enrolled in
PMTCT.
Furthermore, maternal re-testing should be more strongly
emphasized, particularly during breastfeeding and postnatal
follow-up. Approximately 20% of all HIV-positive mothers in
the study identified as HIV-negative or did not know their sta-
tus, and over 50% of HIV-positive mothers with an HIV-posi-
tive infant identified as HIV-negative or did not know their
status. Finally, we found that 8.8% of mothers enrolled in
PMTCT had an HIV-positive infant, which is generally higher
than previous studies in Option B+ settings [25–29]. Although
not nationally representative, these data shed important light
on the ongoing challenges in the fight to eliminate mother-to-
child transmission and suggest a need to strengthen each step
in the PMTCT cascade in order to achieve ambitious elimina-
tion goals [30].
Several limitations exist within this study. The study was not
designed as a nationally representative generalizable survey;
however, healthcare facilities were selected from each of the
four major geographies of Uganda. Mbarara and Mbale Regio-
nal Referral Hospitals and Mulago National Referral Hospital
had similar HIV-positive case numbers and prevalence for
each entry point indicating that the data are not isolated to
specific regions or facilities; however, Lacor had lower preva-
lence at most entry points, comparatively. We suspect that
this may have been due to higher PMTCT and Option B+ cov-
erage at Lacor. These differences could account for the vari-
ability in the prevalence observed across the healthcare
facilities. In addition, only high volume healthcare facilities with
distinct entry points were included to allow for EID testing
volumes to be comparable to the infant volumes at other
entry points and to clearly address our proposed hypothesis
with an efficient approach. Though the results cannot immedi-
ately be extrapolated to smaller healthcare facilities, it is pos-
sible that these findings can be applied to smaller healthcare
facilities through thoughtful implementation considerations.
Infants suspected of malnutrition or in need of referral to
Table 3. PMTCT characteristics of HIV-positive mother study participants
Total, N = 324 (100%) Total, N = 94 (29%) Total, N = 230 (71%)
All HIV-positive
mothers, n (%)
HIV-positive mothers with
HIV-positive infants, n (%)
HIV-positive mothers
with HIV-negative infants, n (%)
Mother’s knowledge of own status
Self-identified positive 259 (79.9) 44 (46.8) 215 (93.5)
Self-identified negative 19 (5.9) 15 (16.0) 4 (1.7)
Self-identified unknown 46 (14.2) 35 (37.2) 11 (4.8)
Mother-infant pair enrolled in PMTCT
Yes 194 (59.9) 17 (18.1) 177 (77.0)
No 130 (40.1) 77 (81.9) 53 (23.0)
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inpatient facilities could be prioritized for routine testing.
Finally, due to the robust patient selection process, limited
bias could be expected. However, we acknowledge that our
study was primarily limited to facility-based services, besides
the outreach entry point, and included only those infants who
presented to the entry points examined.
As low-resource, high HIV burden countries continue to
face funding challenges, national government and global poli-
cymakers are seeking cost-effective, high impact interventions
to reach the UNAIDS 90-90-90 targets [31]. National EID
programmes across sub-Saharan Africa are currently not
providing access to EID testing to a significant proportion of
HIV-exposed infants. Universal virological testing using con-
ventional laboratory-based or point-of-care EID testing at
nutrition, inpatient and outpatient entry points should, there-
fore, be prioritized and implemented as routine practice at all
healthcare facilities.
5 | CONCLUSIONS
The HIV prevalence at the nutrition and inpatient wards were
9.8% and 3.5% (p < 0.001 compared to PMTCT). Expanding
routine early infant diagnosis screening beyond the traditional
PMTCT setting to nutrition and inpatient entry points will
increase the identification of HIV-infected infants. Further-
more, maternal re-testing at immunization, outreach and dur-
ing postnatal follow-up may help identify those mother-baby
pairs missed as well as incident maternal infections. These
findings may help HIV care programmes significantly expand
testing to improve access to early infant diagnosis and paedi-
atric treatment.
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